OverviewSuggest Edit

Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.
TypePublic
Founded2007
HQHellerup, DK
Websiteascendispharma.com
Employee Ratings2.9
Overall CultureB

Latest Updates

Employees (est.) (Jul 2021)482
Share Price (Sept 2021)$161(-1%)
Cybersecurity ratingAMore

Key People/Management at Ascendis Pharma

Jan Møller Mikkelsen

Jan Møller Mikkelsen

President and CEO, Director
Flemming Steen Jensen

Flemming Steen Jensen

Senior Vice President, Product Supply
Vibeke Miller

Vibeke Miller

Senior Vice President, Nonclinical Development and Bioanalysis
Michael Wolff Jensen

Michael Wolff Jensen

Chairman & Senior Vice President, Chief Legal Officer
Jesper Høiland

Jesper Høiland

Senior Vice President, Global Chief Commercial Officer
Kennett Sprogøe

Kennett Sprogøe

Senior Vice President, Chief Financial Officer
Show more

Ascendis Pharma Office Locations

Ascendis Pharma has offices in Hellerup, Palo Alto and Heidelberg
Hellerup, DK (HQ)
5 Tuborg Blvd.
Heidelberg, DE
584 Im Neuenheimer Feld
Palo Alto, CA, US
500 Emerson St
Show all (3)

Ascendis Pharma Financials and Metrics

Ascendis Pharma Revenue

Market capitalization (8-Sept-2021)

8.7b

Closing stock price (8-Sept-2021)

161.0
Ascendis Pharma's current market capitalization is $8.7 b.
Show all financial metrics

Ascendis Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Ascendis Pharma Online and Social Media Presence

Embed Graph

Ascendis Pharma Company Culture

  • Overall Culture

    B

    79/100

  • CEO Rating

    C-

    67/100

  • Compensation

    B

    79/100

Learn more on Comparably

Ascendis Pharma News and Updates

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

– TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation of IL-2Rβ/γ with low Cmax –

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

– Announced U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

- SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –

Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and…

Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

COPENHAGEN, Denmark, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidates that address unmet medical needs, today announced that the company will participate in two upc…
Show more

Ascendis Pharma Frequently Asked Questions

  • When was Ascendis Pharma founded?

    Ascendis Pharma was founded in 2007.

  • Who are Ascendis Pharma key executives?

    Ascendis Pharma's key executives are Jan Møller Mikkelsen, Flemming Steen Jensen and Vibeke Miller.

  • How many employees does Ascendis Pharma have?

    Ascendis Pharma has 482 employees.

  • Who are Ascendis Pharma competitors?

    Competitors of Ascendis Pharma include Libbs Farmaceutica, Servier and Patheon.

  • Where is Ascendis Pharma headquarters?

    Ascendis Pharma headquarters is located at 5 Tuborg Blvd., Hellerup.

  • Where are Ascendis Pharma offices?

    Ascendis Pharma has offices in Hellerup, Palo Alto and Heidelberg.

  • How many offices does Ascendis Pharma have?

    Ascendis Pharma has 3 offices.